NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real-life Treatment Outcomes of Ravulizumab in PNH

Active Not RecruitingN/A

Sponsor: AstraZeneca

Conditions: Paroxysmal Nocturnal Haemoglobinuria

Interventions: Ravulizumab

Countries: Poland

The PNH-RECORD study, a Polish multicenter observational (non-interventional), open-label, retrospective with prospective follow-up.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Adult (aged ≥18) patients with PNH receiving ravulizumab treatment in the frames of NDP in Poland.
2. Patients willing to participate in the study and signed ICF.

Exclusion Criteria:

1. Those who participated in ravulizumab clinical trial in the past, and/or those who participated/plans to participate in clinical trial on/after the date of first ravulizumab infusion through NDP.
2. Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Locations (11)

Bialystok, Poland
Brzozów, Poland
Bydgoszcz, Poland
Gdansk, Poland
Krakow, Poland
Lodz, Poland
Lublin, Poland
Opole, Poland
Szczecin, Poland
Warsaw, Poland
Wałbrzych, Poland